Department of Internal Medicine, Department of Medicine, Loma Linda University, Loma Linda, CA, United States.
Department of Oncology/Hematology, Department of Medicine, Loma Linda University, Loma Linda, CA, United States.
Front Immunol. 2022 Aug 16;13:993622. doi: 10.3389/fimmu.2022.993622. eCollection 2022.
The prognosis of sarcomatoid renal cell carcinoma has changed dramatically with the emergence of immune checkpoint inhibitors. Notably the use of nivolumab and ipilimumab combination therapy has demonstrated promising durable therapeutic response for patients with treatment-naïve sarcomatoid renal-cell carcinoma. We present a case of 45-year-old man with a history of metastatic sarcomatoid renal cell carcinoma treated with nivolumab plus ipilimumab who developed type 1 diabetes mellitus, adrenal insufficiency, thyroiditis/hypothyroidism, and acute interstitial nephritis as a result of immunotherapy.
随着免疫检查点抑制剂的出现，肉瘤样肾细胞癌的预后发生了显著变化。值得注意的是，纳武单抗和伊匹单抗联合治疗方案在未经治疗的肉瘤样肾细胞癌患者中显示出了有希望的持久治疗反应。我们报告了一例 45 岁男性病例，该患者患有转移性肉瘤样肾细胞癌，曾接受纳武单抗联合伊匹单抗治疗，结果发生了 1 型糖尿病、肾上腺皮质功能不全、甲状腺炎/甲状腺功能减退症和急性间质性肾炎等免疫治疗相关不良反应。
